1–10 of 24 results for Wet AMD (neovascular)
The Role of Subretinal Surgery in the Treatment of Resistant Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Nabil M. Jabbour, MD, FACS
On Demand Cases, Courses, and Papers
2021
Real World Experience of Brolucizumab for Persistent Macular Fluid in Neovascular Age-Related Macular Degeneration After Prior Anti-VEGF Treatments
Rehan M. Hussain, MD
Annual Meeting Talks
Subretinal Delivery of RGX-314 for Neovascular AMD: End of Study Phase I/IIa Results
Lejla Vajzovic, MD, FASRS
Safety Results of ONS-5010, an Ophthalmic Bevacizumab, in Treated Eyes of Patients With Wet AMD, DME, and BRVO
Suber S. Huang, MD, MBA, FASRS
Efficacy and Durability of Brolucizumab in Patients Being Transitioned From Prior Anti-VEGF Therapy
Scott D Walter, MD, MSc, FASRS
AI-Based Spatiotemporal Observations of Retinal Fluid Dynamics Using the Notal Vision Home OCT
Anat Loewenstein, MD
Updates from the Field
2022
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Longitudinal Total Retinal Fluid Index Assessment in nAMD From the OSPREY Study: A Novel Assessment of Fluid Drying Effect
Sunil Srivastava, MD
2020
Early Fluid-Free Status & Long-Term BCVA Outcomes With Anti-VEGF Treatment in nAMD: Post Hoc Analysis of Pooled Data From HAWK & HARRIER Studies
Chirag D. Jhaveri, MD, FASRS